‘Great Optimism’ Over Complete Responses in dMMR Rectal Cancer

A small trial shows that patients with locally advanced rectal cancer and deficient mismatch repair tumors respond remarkably well to neoadjuvant PD-1 blockade with dostarlimab.
Medscape Medical News
A small trial shows that patients with locally advanced rectal cancer and deficient mismatch repair tumors respond remarkably well to neoadjuvant PD-1 blockade with dostarlimab.
Medscape Medical News